Seres Therapeutics' (MCRB) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB - Free Report) in a research report released on Thursday morning,Benzinga reports. Chardan Capital currently has a $1.25 price target on the biotechnology company's stock.

Other equities analysts have also issued research reports about the company. StockNews.com upgraded Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, March 6th. The Goldman Sachs Group dropped their target price on shares of Seres Therapeutics from $1.00 to $0.75 and set a "sell" rating on the stock in a research report on Friday, March 14th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $4.00.

Seres Therapeutics Trading Up 0.3 %

MCRB stock traded up $0.00 on Thursday, hitting $0.71. 677,460 shares of the company's stock traded hands, compared to its average volume of 3,403,464. The stock has a market cap of $124.34 million, a price-to-earnings ratio of -3.10 and a beta of 2.19. Seres Therapeutics has a 1-year low of $0.54 and a 1-year high of $1.53. The stock has a fifty day moving average of $0.78 and a 200-day moving average of $0.83.

Remove Ads

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC grew its stake in shares of Seres Therapeutics by 77.2% in the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock valued at $1,505,000 after buying an additional 788,762 shares in the last quarter. Vontobel Holding Ltd. grew its position in Seres Therapeutics by 137.6% in the fourth quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company's stock worth $780,000 after acquiring an additional 543,469 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Seres Therapeutics by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company's stock worth $1,314,000 after purchasing an additional 255,014 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company's stock valued at $708,000 after purchasing an additional 222,771 shares in the last quarter. Finally, FMR LLC lifted its stake in shares of Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company's stock valued at $21,625,000 after purchasing an additional 140,096 shares during the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.